LAKES COMMUNITY CENTER 

WHERE NATURE IS YOUR NEIGHBOR

Important Dates

Saturday - May 22

Trash Day @ LCC 9:00am

Thursday - June 3

Community Center Meeting @LCC 7:00pm

Saturday - June 5

Town Council @LCC 8:30am

Saturday - May 22

Trash Day @ LCC 9:00am

Thursday - June 3

Community Center Meeting @LCC 7:00pm

Saturday - June 5

Town Council @LCC 8:30am

Thursday - June 10

49er Committee Mtg. @LCC 7:00pm

Saturday- June 12

Chipping Day @LCC 9:00am - noon

SAFETY INFO
Check here for recent information on road closures, fires and weather updates.

‘We have been proud to get a solid brand built on almost 75 years of serving the city as a locally-structured, community-minded health strategy,’ said Andrew Dreyfus, CEO and President of BCBSMA. ‘Our solid legacy of community involvement, corporate citizenship, the world-class service we offer to our members/employer clients, and the commitment of our associates will be improved through our new concentrate areas and goals because they continue steadily to roll out.’ Blue Cross Blue Shield of Massachusetts’ Community Commitment For pretty much 75 years BCBSMA provides been serving the city as a locally-structured, community-minded health strategy. Through strategic expenditure, targeted initiatives, and the involved civic leadership of our associates, BCBSMA is definitely a catalyst for enhancing the health, vitality, and educational excellence of households facing economic problem in the Commonwealth through its four concentrate regions of: healthy child advancement, education enrichment, healthy conditions/family diet, and sustainable healthcare..13, 2015- – Baxter International Inc. today announced excellent results from its Stage III medical trial evaluating the protection and efficacy of BAX 817, an investigational recombinant aspect VIIa treatment for those who have hemophilia A or B who develop inhibitors. The potential, open-label, randomized, multicenter trial was made to assess the protection and efficacy of BAX 817 in male sufferers ages 12 to 65 with hemophilia A or B with inhibitors over a 6-month period using on-demand therapy. The trial fulfilled its major endpoint of successful quality of severe bleeding episodes at 12 hours with both on-demand treatment regimens, dosing either 3×90 µg/kg or 1×270 µg/kg, with a standard success rate of 92 % .